Prometrium Bone Health and Density Impact

Does Prometrium have a bone indication?

No. The current label lists exactly two indications: prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets, and secondary amenorrhea [1]. Osteoporosis prevention and osteoporosis treatment are not among them. The labeled endometrial-protection regimen is 200 mg at bedtime for 12 days sequentially per 28-day cycle, alongside daily conjugated estrogens [1].

That distinction matters when reading bone headlines. 'Hormone therapy protects bone' and 'progesterone protects bone' are different claims, and only the first is supported by the trials below.

What the PEPI bone results actually showed

PEPI randomized 875 healthy postmenopausal women aged 45 to 64 to five arms for 3 years: placebo, conjugated equine estrogen (CEE) 0.625 mg daily, CEE plus cyclic medroxyprogesterone acetate 10 mg, CEE plus continuous medroxyprogesterone acetate 2.5 mg, or CEE plus cyclic micronized progesterone 200 mg for 12 days a month [2].

At 36 months the placebo group had lost an average of 1.8% of spine BMD and 1.7% of hip BMD. Every active arm gained: mean total spine increases ranged from 3.5% to 5.0%, with a mean hip increase of 1.7%, and the changes on active treatment were significantly greater than on placebo [2]. The CEE-plus-continuous-medroxyprogesterone arm gained about 5% at the spine, more than the other three active arms (average 3.8%); among women who adhered to their assigned treatment, differences between the four active arms were no longer significant [2].

The detail that decides this page: CEE alone increased bone density. The micronized progesterone arm gained bone inside a regimen that contained estrogen, and the trial design cannot credit the progesterone component.

What micronized progesterone did on its own

The clearest test of progesterone without estrogen is Liu and Muse's 2-year, double-blind, placebo-controlled trial in 132 menopausal women, with six arms: micronized progesterone 300 mg/day, medroxyprogesterone acetate 10 mg/day, norethindrone 1 mg/day, micronized estradiol 1 mg/day, estradiol 1 mg/day plus medroxyprogesterone acetate 10 mg/day, and placebo [3].

BMD at L2-L4 rose 2% to 4% over 2 years with estradiol or estradiol plus medroxyprogesterone acetate. Spine BMD followed a decreasing trend with micronized progesterone, medroxyprogesterone acetate and placebo, and at the femoral neck no group changed significantly. Bone resorption and formation markers fell with the estradiol-containing treatments and did not change appreciably with any of the three progestin-alone arms, and no vertebral or hip fractures occurred during the trial [3]. The investigators concluded that estrogen remains the primary bone-active agent in hormone therapy and that progestins have significantly less activity [3].

Does hormone therapy reduce fractures?

As a category, yes, in the right population. The 2022 North American Menopause Society position statement says hormone therapy has been shown to prevent bone loss and fracture, and that its risks differ by type, dose, duration of use, route of administration, timing of initiation and whether a progestogen is used. For women younger than 60 or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio is favorable for bothersome vasomotor symptoms and for prevention of bone loss; for women who start more than 10 years after menopause or who are older than 60, the ratio appears less favorable [6].

The FDA's February 12, 2026 labeling announcement makes a related point: the agency has approved multiple hormone therapies for preventing bone loss, and randomized studies show that women who initiate hormone therapy within 10 years of menopause onset, generally before age 60, have a reduction in all-cause mortality and fractures [5].

Neither statement turns Prometrium into an osteoporosis drug. Both describe hormone therapy as a category, while Prometrium's own labeled indications remain endometrial protection with conjugated estrogens and secondary amenorrhea [1].

Where micronized progesterone fits

Two points follow directly from the trials:

• When Prometrium is taken alongside conjugated estrogens, the estrogen is the component with the bone-density evidence [2][1].
• Micronized progesterone taken alone, 300 mg daily for 2 years, did not produce the spine bone-density gain seen with estradiol [3].

What the current label says about risk

The current Prometrium label (Revision 02/2026) has no boxed warning. Prometrium was one of the first six menopausal hormone products whose updated labeling FDA approved on February 12, 2026, with the cardiovascular, breast cancer and probable dementia boxed-warning language removed; the Women's Health Initiative estrogen-plus-progestin data remain in the Warnings and Clinical Studies sections [5][7][4].

Labeled contraindications include known, suspected or prior breast cancer; active or prior deep vein thrombosis or pulmonary embolism; active or prior arterial thromboembolic disease such as stroke or myocardial infarction; abnormal genital bleeding of unknown cause; known liver dysfunction or disease; and allergy to peanuts, because the capsules contain peanut oil [1]. The label also states that the drug may cause transient dizziness and drowsiness and that it should be taken as a single daily dose at bedtime [1].

One attribution note on the risk figures in the label: the Women's Health Initiative trial that generated them used conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg, not micronized progesterone [8].